234 related articles for article (PubMed ID: 37878007)
1. Single-cell analysis reveals exosome-associated biomarkers for prognostic prediction and immunotherapy in lung adenocarcinoma.
Lin S; Zhou S; Han X; Yang Y; Zhou H; Chang X; Zhou Y; Ding Y; Lin H; Hu Q
Aging (Albany NY); 2023 Oct; 15(20):11508-11531. PubMed ID: 37878007
[TBL] [Abstract][Full Text] [Related]
2. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
3. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Feng Y; Zhang X; Yang F; Wang W
Front Immunol; 2023; 14():1115272. PubMed ID: 36776843
[TBL] [Abstract][Full Text] [Related]
4. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
5. Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma.
Tang L; Chen Z; Yang J; Li Q; Wang S; Mo T; Zeng W; Ding H; Pan S
Front Immunol; 2024; 15():1352893. PubMed ID: 38390340
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
8. Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights.
Zhang P; Pei S; Zhou G; Zhang M; Zhang L; Zhang Z
J Cell Mol Med; 2024 Apr; 28(8):e18284. PubMed ID: 38597415
[TBL] [Abstract][Full Text] [Related]
9. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
10. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
[TBL] [Abstract][Full Text] [Related]
11. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
12. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
[TBL] [Abstract][Full Text] [Related]
13. Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature.
Zhang P; Zhang X; Cui Y; Gong Z; Wang W; Lin S
Front Immunol; 2023; 14():1244144. PubMed ID: 37671160
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
15. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
[TBL] [Abstract][Full Text] [Related]
16. The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Ren Q; Xie J; Liu H; Wang W
Front Endocrinol (Lausanne); 2023; 14():1154410. PubMed ID: 37033259
[TBL] [Abstract][Full Text] [Related]
17. Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.
Han T; Wu J; Liu Y; Zhou J; Miao R; Guo J; Xu Z; Xing Y; Bai Y; Hu D
Funct Integr Genomics; 2024 Jan; 24(1):19. PubMed ID: 38265702
[TBL] [Abstract][Full Text] [Related]
18. Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses.
Liu Y; Zhang X; Pang Z; Wang Y; Zheng H; Wang G; Wang K; Du J
Aging (Albany NY); 2024 May; 16(10):8772-8809. PubMed ID: 38771130
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma.
Lu H; Qian J; Cheng L; Shen Y; Chu T; Zhao C
BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38081768
[TBL] [Abstract][Full Text] [Related]
20. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.
Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q
Front Immunol; 2023; 14():1263329. PubMed ID: 37727789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
